Physician profile
Sandhya Ventrapragada
NPI 1265662688
$1,131.41
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42.40 · 2020: $443 · 2021: $486 · 2022: $160.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $245.58 | 2019-2022 | |
| Amgen INC. | $208.80 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $187.62 | 2020-2021 | |
| Amarin Pharma, INC. | $86.59 | 2020-2021 | |
| Lilly USA, LLC | $83.36 | 2020-2021 | |
| Novo Nordisk INC | $67.86 | 2020-2022 | |
| Pfizer INC. | $38.41 | 2020-2021 | |
| Genentech USA, INC. | $32.59 | 2019-2020 | |
| Zealand Pharma US, INC. | $31.03 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $24.56 | 2021 | |
| Ironwood Pharmaceuticals, INC | $17.19 | 2020 | |
| Sanofi Pasteur INC. | $17.14 | 2021 | |
| Biogen, INC. | $16.85 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $16.63 | 2021 | |
| Abbvie INC. | $14.98 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $14.94 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.41 | 2021 | |
| Astellas Pharma US INC | $12.87 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandhya Ventrapragada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.